The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89:3909–3918 Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130 Kadin ME, Berard CW, Nanba K, Wakasa H (1983) Lympho proliferative diseases in Japan and Western countries: proceedings of the United States–Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol 14:745–772 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1:45–50 Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82 Lippman SM, Miller TP, Spier CM, Slymen DJ, Grogan TM (1988) The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 72:436–441 Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467–1475 Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, Ilariucci F, Sacchi S, Vitolo U, Federico M (2004) Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 101:1601–1608 Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS, Flexner JM, Cousar JB, Jagasia MH, McCurley TL, Greer JP (2003) Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 44:241–249 Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38:75–81 Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunet S, Garcia-Conde J, Fernandez de Sevilla A, Bosch F, Montserrat E (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 9:849–855 Melnyk A, Rodriguez A, Pugh WC, Cabannillas F (1997) Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 89:4514–4520 Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977–1984 Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K (2006) Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol 116:90–95 Sung HJ, Kim SJ, Seo HY, Sul HR, Choi JG, Choi IK, Park KH, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS (2006) Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol 134:45–53 Aviles A, Castaneda C, Neri N, Cleto S, Talavera A, Gonzalez M, Huerta-Guzman J, Nambo MJ (2008) Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Med Oncol 25:360–364 Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E, Lopez-Guillermo A (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958–963 Intragumtornchai T, Prayoonwiwat W, Numbenjapon T, Assawametha N, O’Charoen R, Swasdikul D (2000) CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin’s lymphoma. Clin Lymphoma 1:219–225 Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M (2007) VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458–5464 Tey SK, Marlton PV, Hawley CM, Norris D, Gill DS (2008) Post-transplant hepatosplenic T-cell lymphoma successfully treated with hyperCVAD regimen. Am J Hematol 83:330–333 Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091–2098 Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58:35–39 Spencer A, Reed K, Arthur C (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 37:760–766 Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351–1353 Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603–2606 Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92:271–272 Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702–703 Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920–2924 Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 16:3257–3263 Zeitlinger MA, Schmidinger M, Zielinski CC, Chott A, Raderer M (2005) Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert’s lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab. Leuk Lymphoma 46:771–774 Meulenbeld HJ, Spiering W, Nooijen P, Peters W, Creemers GJ (2007) Hepatosplenic gammadelta T-cell lymphoma: a case report. Eur J Intern Med 18:241–243 Halene S, Zieske A, Berliner N (2006) Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol 3:165–168 quiz 169 Gutierrez A, Rodriguez J, Ramos R, Gines J, Sampol A, Galmes B, Besalduch J (2004) Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma. Eur J Haematol 72:377–378 Murdock J, Jaffe ES, Wilson WH, McManus DT, Alexander HD, Morris TC (2004) Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature. Leuk Lymphoma 45:1269–1273 Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K (2007) Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 78:545 Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M (2008) Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol 88:434–440 Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS (2009) Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 20:390–392 Soldini D, Mora O, Cavalli F, Zucca E, Mazzucchelli L (2008) Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol 142:484–486 Jaeger G, Bauer F, Brezinschek R, Beham-Schmid C, Mannhalter C, Neumeister P (2008) Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 19:1025–1026 Mittal S, Milner BJ, Johnston PW, Culligan DJ (2006) A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 76:531–534 Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129–134 Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316–2323 Kluin-Nelemans J, Kooij MVM, Lugtenburg P (2008) Alemtuzumab-CHOP for aggressive T cell lymphoma: a phase II HOVON 69 trial. Blood (ASH Annual Meeting Abstracts) 112: Abstract 1999 Janik JE, Dunleavy K, Pittaluga S, Jaffe ES, Grant N, Shovlin M, Stetler-Stevenson M, Wilson WH (2005) A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood (ASH Annual Meeting Abstracts) 106: Abstract 3348 Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization Classification of Tumours:Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, WHO, Lyon Smolej L (2008) Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Blood 112:2167 O’Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O’Neal B, Kantarjian H, Keating M (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111:1816–1819 Hwang YY, Cheung WW, Leung AY, Tse E, Au WY, Kwong YL (2008) Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy. Leukemia. doi:10.1038/leu.2008.282 Gonzalez H, Vernant JP, Caumes E (2005) Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. Leukemia 19:478 Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586 Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649 Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. doi:10.1093/annonc/mdp211 Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF (2008) Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol 87:727–734 Garcia-Manero G, Kantarjian HM (2000) The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14:1381–1396 x–xi Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 12:7174–7179 Chang ST, Lu CL, Chuang SS (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 48:117–121 Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566–567 Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M (2009) Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 145:173–179 Cheung WW, Tse E, Leung AY, Yuen KY, Kwong YL (2007) Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 82:108–111 Roch N, Salameire D, Gressin R, Morand P, Epaulard O, Pavese P, Brion JP, Stahl JP (2008) Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sezary syndrome. Scand J Infect Dis 40:343–346 Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S (2008) EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 112:1039–1041